A rapid measurement of plasma concentration of a molecular-targeted drugs with diamond sensor.

DOI
  • Ogata Genki
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan
  • Saiki Takuro
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan Department of Medical Oncology, Niigata University School of Medicine, Niigata, Japan
  • Sawamura Sheishiro
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan
  • Razvina Olga
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan
  • Watanabe Kota
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan
  • Kato Rito
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan
  • Asai Kai
    Department of Chemistry, Faculty of Science and Technology, Keio Univ, Yokohama, Japan
  • Hanawa Ai
    Department of Chemistry, Faculty of Science and Technology, Keio Univ, Yokohama, Japan
  • Matsumoto Yoshifumi
    Department of Medical Oncology, Niigata University School of Medicine, Niigata, Japan
  • Saijo Yasuo
    Department of Medical Oncology, Niigata University School of Medicine, Niigata, Japan
  • Einaga Yasuaki
    Department of Chemistry, Faculty of Science and Technology, Keio Univ, Yokohama, Japan
  • Hibino Hiroshi
    Department of Molecular Physiology, Niigata University School of Medicine, Niigata, Japan

Bibliographic Information

Other Title
  • ダイヤモンドセンサを用いた血漿中分子標的薬迅速測定法の開発

Description

<p>Molecular-targeted anticancer drugs elicit less toxicity than conventional reagents. Yet, patients often suffer from severe adverse effects. The reason is "fixed dosage" administration of the drug to all the patients regardless of their body size and complications; because of this strategy, the plasma concentration seems to occasionally exceed the therapeutic window. Although frequent measurement of the drug level at a clinical site is a solution, currently available methods are unsuitable. To overcome this shortcoming, in this study we developed a procedure with an electrochemical sensor composed of conductive diamond, which yields more stable reactions than conventional materials. When guinea-pig plasma mixed with imatinib, lenvatinib, or pazopanib were tested, the sensor detected a clinically relevant concentration. Time and sample amount necessary for each series of the measurement was <1 min and 100 μL, respectively. This method may enable therapeutic drug monitoring of molecular-targeted drugs and accelerate tailored medicine for cancer.</p>

Journal

Details 詳細情報について

  • CRID
    1390285300180911872
  • NII Article ID
    130007884952
  • DOI
    10.11239/jsmbe.annual58.286
  • ISSN
    18814379
    1347443X
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top